WILMINGTON, Delaware, USA – June 8, 2026
Incyte Corporation has announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a transaction valued at up to $2 billion, significantly expanding its hematology portfolio into bleeding disorders. The acquisition includes $1.25 billion in upfront consideration, with Star Therapeutics eligible to receive up to $750 million in additional milestone payments tied to future sales performance. At the center of the transaction is VGA039, a first-in-class investigational monoclonal antibody currently in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder. The strategic acquisition strengthens Incyte’s position in hematology while adding a late-stage clinical asset with blockbuster potential and multiple regulatory designations from the U.S. Food and Drug Administration (FDA). The deal highlights continued consolidation within the biotechnology sector as companies seek innovative therapies capable of addressing significant unmet medical needs while driving long-term growth.
Phase 3 Asset Expands Incyte’s Hematology Leadership
The proposed acquisition brings VGA039, a novel monoclonal antibody targeting Protein S, into Incyte’s growing hematology pipeline. Unlike existing therapies that often require frequent intravenous administration, VGA039 is being developed as a subcutaneous prophylactic treatment with a convenient once-monthly dosing regimen, potentially offering a significant advancement in patient care and treatment adherence. The investigational therapy works by improving hemostasis, helping the body better control bleeding episodes across a range of bleeding disorders. Currently, VGA039 is being evaluated in the Phase 3 VIVID-6 trial, a global study designed to assess the safety and efficacy of the therapy in patients with all forms of von Willebrand disease.
Early clinical data have demonstrated promising potential, positioning the therapy as a possible first-in-class treatment capable of transforming the management of VWD. Company executives emphasized that VGA039 aligns closely with Incyte’s strategy of acquiring innovative late-stage assets capable of driving future growth while addressing diseases with substantial unmet medical need.
Addressing a Significant Need in Von Willebrand Disease
Advertisement
Von Willebrand disease affects approximately 135,000 diagnosed individuals in the United States and is characterized by impaired blood clotting that can lead to recurrent and sometimes severe bleeding episodes. Current prophylactic treatment options frequently rely on factor replacement therapies that require multiple intravenous infusions each week, creating a significant treatment burden for patients. VGA039 has been designed to overcome many of these limitations through a differentiated mechanism of action and a more convenient administration profile.
The therapy has already received several important FDA regulatory designations, including Breakthrough Therapy Designation, Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, highlighting both the severity of the disease and the potential importance of the treatment. If approved, VGA039 could become one of the first therapies capable of providing long-term bleeding protection through monthly subcutaneous administration, offering improved convenience and quality of life for patients living with this chronic inherited disorder.
Strategic Acquisition Strengthens Long-Term Growth Pipeline
The acquisition reflects Incyte’s broader strategy of expanding beyond its established portfolio by acquiring innovative therapies with strong commercial and clinical potential. Company leadership described VGA039 as a first-in-class Phase 3 asset with compelling clinical data, a manageable regulatory pathway, and the potential to become a major growth driver within the company’s hematology franchise. The transaction has been approved by the boards of directors of both companies and is expected to close during the third quarter of 2026, subject to customary regulatory approvals and closing conditions.
Industry analysts view the deal as a significant addition to Incyte’s pipeline, providing immediate entry into the bleeding disorders market while strengthening its position in specialty hematology. As competition intensifies across the biotechnology sector, acquisitions of advanced clinical-stage assets continue to play an important role in portfolio expansion strategies. The addition of VGA039 not only diversifies Incyte’s development portfolio but also reinforces its commitment to delivering innovative therapies for patients with rare and serious hematologic conditions.
Source: Incyte, Vega Therapeutics press release
